Lidia Ukarma

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

Philippe A. Cassier, Antoîne Italiano, Carlos Gomez-Roca et al. · The Lancet Oncology · 2015 · 363 citations

Medicine, Oncology, Pharmacology +14

Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer—Anemia and the Value of Erythropoietin (BRAVE) Study

Matti Aapro, Robert Leonard, Agustí Barnadas et al. · Journal of Clinical Oncology · 2008 · 106 citations · Full text

Medicine, Oncology, Pharmacology +16

Hepcidin as a Predictor of Response to Epoetin Therapy in Anemic Cancer Patients

Lidia Ukarma, Hélène Johannes, Ulrich Beyer et al. · Clinical Chemistry · 2009 · 29 citations · Full text

Medicine, Hematology, Pharmacology +10

OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY

Rebecca Finch, Alexandre Sostelly, Kim Sue-Ling et al. · Annals of the Rheumatic Diseases · 2019 · 23 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

Matti Aapro, Agustí Barnadas, Robert Leonard et al. · European Journal of Cancer · 2009 · 14 citations

Medicine, Oncology, Pharmacology +16